文献速递免疫规划

儿童重复接种MF59佐剂四价流感疫苗的两项再接种研究

Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.
PubMed 文献 · Vaccine · 2020-11-01

两项再接种研究评估儿童重复接种MF59佐剂四价流感疫苗(aQIV)与常规非佐剂四价疫苗(QIV)的安全性和免疫原性。第一季607人、第二季1601人,aQIV再接种对部分毒株血凝抑制GMT比值优于QIV,异源毒株抗体更高,反应原性轻中度但总体安全性与母研究相似。

要点

  • aQIV再接种对部分流感毒株的HI GMT比值优于QIV再接种
  • aQIV接种后异源流感毒株HI滴度更高
  • aQIV反应原性轻中度且短暂,总体安全性与母研究相似

核心结论

  • aQIV对12月龄至7岁儿童的初次免疫和再接种均显示获益。

研究设计与样本

  • 两项再接种研究纳入母研究中接种过aQIV或非佐剂流感疫苗(TIV或QIV)的儿童,第一季607人、第二季1601人。
  • 第一季参与者保持原随机分组(aQIV-aQIV或TIV-QIV),第二季重新随机分为四组(aQIV-aQIV、aQIV-QIV、QIV-aQIV、QIV-QIV),均单剂接种。
  • 接种前及接种后21天和180天采血评估免疫原性,评估第1-7天反应原性和安全性。

主要发现

  • 血凝抑制(HI)几何平均滴度(GMT)比值显示,第一季aQIV再接种对所有毒株优于QIV再接种,第二季对A/H1N1、B/Yamagata和B/Victoria优于QIV再接种。
  • 两季aQIV接种后针对异源流感毒株的HI滴度均更高。
  • aQIV组轻中度、短持续时间反应原性比QIV组更常见,但总体安全性与母研究相似。

临床怎么用

  • 对于12月龄至7岁儿童,aQIV可用于初次免疫和再接种以增强免疫应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pediatric adjuvanted seasonal influenza vaccines induce higher immune responses and have the potential to confer better protection against influenza among young vaccine-naïve children. Limited data describe benefits and risks of repeated administration of adjuvanted influenza vaccines in children. Two revaccination studies assess the safety and immunogenicity of repeated exposure to an MF59-adjuvanted quadrivalent influenza vaccine (aQIV; Fluad®) compared to routine non-adjuvanted quadrivalent influenza vaccine (QIV). METHODS: Children previously enrolled in the parent study, who received vaccination with aQIV or nonadjuvanted influenza vaccine (TIV or QIV), were recruited in Season 1 (n = 607) or Season 2 (n = 1601) of the extension trials. Season 1 participants remained in their original randomization groups (aQIV-aQIV or TIV-QIV); Season 2 subjects were re-randomized to either vaccine, resulting in four groups (aQIV-aQIV, aQIV-QIV, QIV-aQIV, or QIV-QIV). All subjects received a single-dose vaccination. Blood samples were taken for immunogenicity assessment prior to vaccination and 21 and 180 days after vaccination. Reactogenicity (Days 1-7) and safety were assessed in all subjects. RESULTS: Hemagglutination inhibition (HI) geometric mean titer (GMT) ratios demonstrated superiority of aQIV revaccination over QIV revaccination for all strains in Season 1 and for A/H1N1, B/Yamagata, and B/Victoria in Season 2. Higher HI titers against heterologous influenza strains were observed after aQIV vaccination during both seasons. Mild to moderate severity and short duration reactogenicity was more common in the aQIV than QIV groups, but the overall safety profiles were similar to the parent study. CONCLUSION: The safety and immunogenicity results from this study demonstrate benefit of aQIV for both priming and revaccination of children aged 12 months to 7 years.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Vesikari T, Ramsey K, Pitisuttithum P, et al. Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies. Vaccine. 2020. PMID: 33139136. doi:10.1016/j.vaccine.2020.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。